Work

Supplementary Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

Year: 2023

Type: supplementary-materials

Abstract: Table S1. shows progression Free Survival in individual subjects. Table S2. show exposures to epirubicinol in subjects who received infusion of NC-6300. Figure S1. shows total epirubicin concentrations (mean {plus minus} SD) at the end of infusion of 170 mg/m2 NC-6300 across cycles. Figure S2. shows mean Change in EORTC QLQ-C30 Score from Baseline.

DOI: 10.1158/1078-0432.22476185

Authors: Sant P. Chawla, Sanjay Goel, Warren Chow, Fadi Braiteh, Arun S. Singh, Juneko E. Grilley Olson, Atsushi Osada, Iulian Bobe, Richard F. Riedel

Language: English

Topic: Nanoparticle-Based Drug Delivery

Subfield: Biomaterials

Field: Materials Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361888711

Cites:

Cited by:

Related to: 10